Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Data Published Shows Efficiency and Accuracy of Gene Expression Assay Technology

Published: Tuesday, October 03, 2006
Last Updated: Thursday, October 12, 2006
Bookmark and Share
The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay method.

HTG Inc. has announced results from a study measuring gene expression on marker genes have been published in the August 2006 issue of Toxicology in Vitro.

The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay (qNPAT) method versus the standard PCR-based testing approach in testing 12 specific gene markers of drug-induced phospholipidosis on HepG2 cells.

The published data show that the in vitro screening assay for compound-induced phospholipidosis should be transferable from a PCR-based assay to HTG's qNPA, a higher throughput method.

Hiroshi Sawada, Takeda Pharmaceutical Company Limited in Osaka, Japan is the lead author of the article.

The article entitled, "Improved Toxicogenomic Screening for Drug-Induced Phospholipidosis Using a Multiplexed Quantitative Gene Expression ArrayPlate assay," reports outcomes from a follow-on study to a toxicogenomics analysis evaluated in previous research that enables researchers to identify sets of gene markers for various toxic conditions.

These findings published in Toxicology in Vitro, the official journal of the European Society of Toxicology in Vitro, confirm the qNPA approach is beneficial in setting up toxicogenomics-based assay systems to further evaluate these gene markers.

The qNPA was tested on the following measures: sensitivity, repeatability and correlation.

Results demonstrated the expression of mRNA for all target genes was detected at quantifiable levels, the signal intensities and fold change values of each marker gene were highly repeatable and there was a high correlation between results gained from the qNPA and real-time PCR assays.

"We are thrilled Takeda recognizes the qNPA technology as a useful, investigative tool in evaluating toxicogenomics analysis," said Bill Radany, president and CEO, HTG.

"HTG is enabling high-throughput screening for mainstream drug discovery and is a cost effective alternative to PCR."

HTG's ArrayPlate qNPAT technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.

HTG's ArrayPlate lysis-only quantitative Nuclease Protection Assay (qNPAT) platform is designed to allow scientists to test any sample while avoiding the need for extraction or target amplification.

The platform is designed to provide high-quality quantitative test results, including QSAR-quality dose response data and EC50's.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!